New drug combo aims to shrink HPV-Caused growths in lungs and throat
NCT ID NCT04645602
First seen Nov 15, 2025 · Last updated Jun 08, 2026 · Updated 21 times
Summary
This early-phase study tests two drugs, lenvatinib and pembrolizumab, in 20 adults with HPV-related recurrent respiratory papillomatosis (RRP) that has spread to the lungs. The goal is to see if the combination can shrink growths and reduce the need for repeated surgeries. Participants will be monitored for side effects and changes in disease burden.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.